Female pattern hair loss

Chan, Linda; Cook, David

doi:10.31128/ajgp-02-18-4498

Cited by 21 publications

(30 citation statements)

References 14 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hirsutism results from the interplay of the systemic and local androgens levels versus selective sensitivity and response of the pilosebaceous units' to androgens expression [14,15]. The fact that explains the limited indirect relationship between androgen level and the hirsutism severity and why the hirsutism does not always indicate hyperandrogenemia [15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…Scores ≤8/36 is the currently accepted figure for Middle-Eastern women, including Iraqi women. The hirsutism severity was graded according to (mFG) to mild (mFG score≤15), moderate (mFG score [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25], and severe hirsutism (mFG score >25), or having no hirsutism (mFG score≤8) [6].…”

Section: Figure 1: Flow Chart Of the Inclusion And Exclusion Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Is There Any Association Between Clinical and Biochemical Hyperandrogenism in Women With Female Pattern Hair Loss?

Odhaib¹,

Hamdi²,

Mansour³

2020

Cureus

View full text Add to dashboard Cite

Background The exact association between clinical and biochemical hyperandrogenism (HA) is heterogeneous and cannot be ascertained, especially in normoandrogenic women. Objectives Evaluate any association between clinical phenotypes and biochemical parameters of HA in premenopausal women with female pattern hair loss (FPHL). Materials and methods A cross-sectional observational study on 362 women, who were assessed for general characteristics, the different FPHL severities by Sinclair's score, hirsutism by modified Ferriman-Gallwey (mFG) score. Evaluation for biochemical HA included total, calculated free and bioavailable testosterone (TT), free testosterone (FT), and bioavailable testosterone (BT), respectively, and dehydroepiandrosterone sulfate. The variables of clinical HA were FPHL, hirsutism, and acne. Results The enrolled young premenopausal women's age range was (14-47 years). Around 78% were overweight or obese women. Eighty-percent of women had a mild FPHL, with a median of three years, where 2/3 of women had a duration <3 years with no significant relationship to FPHL severity. About 73% of women had either a mild to moderate hirsutism, and around 16% had acne. The biochemical HA was confirmed in around 52% of women (n=188), who show high levels of calculated FT. The calculated BT is high in 78.5% of women (n=284). The means of HA's biochemical indicators were in their reference ranges or slightly above, with no specific change pattern with the corresponding FPHL severity. None of these parameters had a significant relationship with the severity of FPHL. The FPHL duration was not affected by any presumed variable of clinical or biochemical HA. Conclusions FPHL severity was associated with other clinical HA signs like hirsutism and acne, but not to HA's biochemical parameter. Other parameters, like sex hormone-binding globulin (SHBG), and BMI, had no significant relation to the FPHL severity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Figure 1: Flow Chart Of the Inclusion And Exclusion Criteriamentioning

confidence: 99%

Is There Any Association Between Clinical and Biochemical Hyperandrogenism in Women With Female Pattern Hair Loss?

Odhaib¹,

Hamdi²,

Mansour³

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…The exposure to androgens is the major triggers for hair loss is which in most cases is genetically predetermined in androgenic alopecia patients [9,31,32].…”

Section: Ginseng On Androgen Alopeciamentioning

confidence: 99%

Ginseng in Hair Growth and Viability

Mercedes¹,

Ruymán²,

Noelia³

et al. 2022

Ginseng - Modern Aspects of the Famed Traditional Medicine

View full text Add to dashboard Cite

The hair follicle is the unique organ that has the capacity of undergoing cyclic transformations following periods of growth (anagen), regression (catagen), and rest (telogen) regenerating itself to restart the cycle. The dynamic capacity of hair to growth and rest enables mammals to control hair growth and length in different body side and to change their coats. Unlike what is observed in many animals in which the pelage synchronously passes from one phase of the cycle to other all stages of growth cycle are simultaneously found in the human pelage, the growth pattern is a mosaic where the hair cycling staging of one hair root is completely independent of it nearest hair follicle, meaning that each follicular unit (FU) can contain follicles in different stages at any given time. A variety of factors, such as nutritional status, hormones, exposure to radiations, chemotherapy or radiotherapy, environmental pollution or drugs may affect hair growth, and affects the number of hairs, this progressive hair loss has a cosmetic and social impact that often significantly affects social and psychological well-being of the patient that suffers from this hair loss. Although a number of therapies, such as finasteride and minoxidil, are approved medications, a wide variety of classes of phytochemicals and natural products, including those present in ginseng are being testing. The purpose of this chapter is to focus on study the potential of ginseng and its metabolites in hair loss.

show abstract

“…Other forms of alopecia that may present similarly to male and female pattern hair loss include telogen effl uvium, alopecia areata, traction alopecia, trichotillomania, central centrifugal cicatricial alopecia, lichen planopilaris, and frontal fi brosing alopecia (Figure 3). 15,16 Telogen effl uvium, a condition of noninfl ammatory, diffuse hair loss, is often diffi cult to distinguish from female pattern hair loss. A thorough history is very important, as there is generally an inciting trigger such as psychological stress, childbirth, weight loss, or medications (eg, interferons, antihyperlipidemic medications, derivatives of retinol, anticoagulants) that precedes telogen effl uvium by a few months.…”

Section: ■ Differential Diagnosismentioning

confidence: 99%